<DOC>
	<DOCNO>NCT00967304</DOCNO>
	<brief_summary>The main objective study verify whether new clinical decision rule identify patient diagnose unprovoked blood clot low risk recurrence safely stop oral anticoagulant therapy 5-7 month treatment .</brief_summary>
	<brief_title>Clinical Decision Rule Validation Study Predict Low Recurrent Risk Patients With Unprovoked Venous Thromboembolism</brief_title>
	<detailed_description>Up 50 % patient first episode venous thromboembolism ( VTE ) identifiable cause ( i.e . unprovoked VTEs ) . The risk recurrent VTE large group patient unprovoked VTE 3-6 month anticoagulant therapy 5-10.8 % year follow discontinuation oral anticoagulant therapy . One six one twenty recurrences new VTE fatal . Given intermediate risk recurrence unselected unprovoked VTE patient , clinician clear guidance whether continue discontinue anticoagulant patient unprovoked VTE . Recently attention turn concept risk stratification identify subgroups patient unprovoked VTE could safely discontinue oral anticoagulation therapy ( OAT ) . In REVERSE I study , clinical decision rule derivation study conduct 2001 2006 , develop internally validate clinical decision rule `` Men continue HER DOO2 '' identify patient first unprovoked VTE likely low risk recurrent VTE could safely discontinue OAT subsequent 5-7 month OAT . The present study evaluate `` Men continue HER DOO2 '' rule ( comprise gender , elevate D-dimer level , post-thrombotic sign , obesity , old age ) safe , clinically useful , reproducible prospectively implement multiple center variety setting . If clinical decision rule validate , provide physician important information allow confidently identify unprovoked VTE patient low risk VTE recurrence may need continue OAT .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>First episode major unprovoked VTE VTE objectively proven VTE treat 512 month anticoagulant therapy authorize REVERSE II study ( initial ongoing therapy ) Absence recurrent VTE treatment period Less 18 year age Patients already discontinue anticoagulant therapy Patients require ongoing anticoagulation reason VTE Being treat recurrent unprovoked VTE Patients high risk thrombophilia patient plan use exogenous estrogen ( OCP , HRT ) anticoagulant therapy discontinue Patients pregnancy associate VTE Geographically inaccessible followup Patients unable unwilling provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Unprovoked Venous thromboembolism</keyword>
	<keyword>Clinical decision rule</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Prognostic</keyword>
	<keyword>Risk stratification</keyword>
</DOC>